Complete Filing Data
Greenwich LifeSciences, Inc. reported Stockholders Equity of $13.21 million for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Greenwich LifeSciences, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$15.8M | -$8.9M | -$7.8M | -$4.6M | -$1.9M | -$3.4M |
| Research And Development Expense | $13.0M | $7.7M | $6.5M | $3.6M | $1.1M | $2.6M |
| Operating Income Loss | -$16.0M | -$9.3M | -$8.0M | -$4.6M | -$1.9M | -$3.4M |
| Operating Expenses | $16.0M | $9.3M | $8.0M | $4.6M | $1.9M | $3.4M |
| General And Administrative Expense | $3.1M | $1.6M | $1.6M | $1.0M | $806.2K | $818.9K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$4.2M | -$4.0M | -$3.3M | -$2.7M | -$2.6M | -$2.5M | -$2.4M | -$1.6M | -$2.1M | -$2.3M | -$746.1K | -$2.0M | -$863.1K | -$749.7K | -$597.0K | -$256.9K | -$210.4K | -$244.6K | -$336.0K | -$2.6M | -$148.7K |
| Research And Development Expense | $3.5M | $3.5M | $2.6M | $2.3M | $2.3M | $2.2M | $2.2M | $1.4M | $1.8M | $1.7M | $633.3K | $1.7M | $657.1K | $556.5K | $282.0K | $158.0K | $150.8K | $149.9K | $284.5K | ||
| Operating Income Loss | -$4.2M | -$4.0M | -$3.3M | -$2.7M | -$2.7M | -$2.5M | -$2.5M | -$1.7M | -$2.2M | -$2.4M | -$773.3K | -$2.0M | -$866.7K | -$753.4K | -$600.6K | -$256.9K | -$210.4K | -$244.6K | -$336.0K | ||
| Operating Expenses | $4.2M | $4.0M | $3.3M | $2.7M | $2.7M | $2.5M | $2.5M | $1.7M | $2.2M | $2.4M | $773.3K | $2.0M | $866.7K | $753.4K | $600.6K | $256.9K | $210.4K | $244.6K | $336.0K | ||
| General And Administrative Expense | $653.1K | $538.0K | $681.2K | $437.0K | $353.5K | $342.7K | $344.8K | $368.3K | $413.2K | $659.6K | $140.1K | $328.4K | $209.6K | $196.9K | $318.6K | $98.8K | $59.6K | $94.8K | $51.5K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $13.2M | $26.8M | $27.6M | -$1.4M | -$10.1M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $27.2M | $28.7M | $6.8K | $85.1K | |||
| Retained Earnings Accumulated Deficit | -$50.4M | -$41.5M | -$33.6M | -$29.1M | -$27.2M | ||
| Liabilities Current | $294.4K | $262.9K | $385.2K | $1.0M | $1.4M | ||
| Liabilities And Stockholders Equity | $7.0M | $13.5M | $27.2M | $28.7M | $26.7K | ||
| Liabilities | $294.4K | $262.9K | $385.2K | $1.0M | $1.4M | ||
| Common Stock Value | $12.8K | $12.8K | $13.1K | $12.7K | $8.5K | ||
| Cash And Cash Equivalents At Carrying Value | $7.0M | $13.5M | $27.2M | $28.7M | $6.8K | ||
| Assets | $7.0M | $13.5M | $27.2M | $28.7M | $26.7K | ||
| Accounts Payable And Accrued Liabilities Current | $256.3K | $220.8K | $220.8K | $711.0K | $730.3K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$2.9M | -$6.5M | -$13.7M | -$1.5M | $28.7M | -$78.3K | |
| Finite Lived Intangible Assets Net | $5.4K | $9.0K | $12.6K | $16.2K | $19.8K | ||
| Employee Related Liabilities Current | $38.1K | $42.1K | $164.3K | $59.4K | $11.6K | ||
| Additional Paid In Capital Common Stock | $57.1M | $54.7M | $60.5M | $56.7M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $13.5M | ||||||
| Assets Current | $6.8K | ||||||
| Repayments Of Related Party Debt | $360.0K | ||||||
| Issuance Of Preferred Stock Due To Antidilution | $42.00 | ||||||
| Exercise Of Common Stock From Green Shoe Of Followon Offering Net Of Offering Costs | $2.5M | ||||||
| Stock Issued During Period Value Exchange Of Related Party Payables And Warrants For Common Stock | $12.0M | ||||||
| Issuance Of Common Stock Through Partial Exercise Of Underwriter Warrants | $562.6K | ||||||
| Deferred Compensation Liability Current And Noncurrent | |||||||
| Deferred Offering Costs | |||||||
| Deferred Compensation Liability Current | |||||||
| Accrued Liabilities Current |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $2.2M | $1.4M | $1.3M | $2.5M | $5.0M | $5.9M | $5.1M | $6.7M | $8.9M | $10.6M | $11.7M | $15.4M | $17.0M | $19.5M | $28.5M | $29.2M | $29.7M | $4.7M | -$1.5M | -$1.4M | -$1.2M | -$12.9M | -$10.3M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $7.2M | $5.5M | $7.0M | $9.1M | $10.9M | $11.9M | $13.5M | $15.6M | $17.2M | $19.7M | $28.9M | $29.8M | $30.4M | $6.2M | $6.8K | $6.8K | $6.0K | ||||||||
| Retained Earnings Accumulated Deficit | -$77.6M | -$73.4M | -$69.4M | -$66.2M | -$58.1M | -$55.4M | -$52.8M | -$47.6M | -$45.2M | -$43.6M | -$38.7M | -$36.4M | -$35.6M | -$31.3M | -$30.4M | -$29.7M | -$27.9M | ||||||||
| Liabilities Current | $1.6M | $1.7M | $1.4M | $1.6M | $842.4K | $1.4M | $389.6K | $297.3K | $301.5K | $235.6K | $237.9K | $229.1K | $241.2K | $455.1K | $652.6K | $673.1K | $1.6M | ||||||||
| Liabilities And Stockholders Equity | $3.8M | $3.1M | $2.8M | $4.1M | $5.8M | $7.2M | $5.5M | $9.1M | $11.0M | $11.9M | $15.6M | $17.2M | $19.8M | $28.9M | $29.8M | $30.4M | $6.3M | ||||||||
| Liabilities | $1.6M | $1.7M | $1.4M | $1.6M | $842.4K | $1.4M | $389.6K | $297.3K | $301.5K | $235.6K | $237.9K | $229.1K | $241.2K | $455.1K | $652.6K | $673.1K | $1.6M | ||||||||
| Common Stock Value | $13.8K | $13.5K | $13.2K | $13.2K | $13.1K | $13.1K | $12.9K | $12.8K | $12.8K | $12.8K | $12.8K | $12.8K | $13.0K | $13.0K | $12.9K | $12.8K | $12.0K | ||||||||
| Cash And Cash Equivalents At Carrying Value | $3.8M | $3.1M | $2.7M | $4.1M | $5.8M | $7.2M | $5.5M | $9.1M | $10.9M | $11.9M | $15.6M | $17.2M | $19.7M | $28.9M | $29.8M | $30.4M | $6.2M | ||||||||
| Assets | $3.8M | $3.1M | $2.8M | $4.1M | $5.8M | $7.2M | $5.5M | $9.1M | $11.0M | $11.9M | $15.6M | $17.2M | $19.8M | $28.9M | $29.8M | $30.4M | $6.3M | ||||||||
| Accounts Payable And Accrued Liabilities Current | $1.1M | $1.3M | $1.0M | $1.2M | $774.8K | $1.3M | $346.6K | $230.9K | $300.5K | $220.8K | $220.8K | $220.8K | $220.8K | $295.8K | $627.6K | $609.3K | $800.2K | ||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$1.3M | -$1.5M | -$1.6M | -$7.5M | $1.7M | ||||||||||||||||||||
| Finite Lived Intangible Assets Net | $876.00 | $1.8K | $2.7K | $3.6K | $4.5K | $6.3K | $7.2K | $8.1K | $9.9K | $10.8K | $11.7K | $13.5K | $14.4K | $15.3K | $17.1K | ||||||||||
| Employee Related Liabilities Current | $206.8K | $84.4K | $75.9K | $67.6K | $17.8K | $43.0K | $66.4K | $1.1K | $14.7K | $17.0K | $8.3K | $20.3K | $159.3K | $25.0K | $63.8K | $138.0K | |||||||||
| Additional Paid In Capital Common Stock | $79.8M | $74.9M | $70.7M | $68.7M | $63.1M | $61.3M | $57.9M | $56.5M | $55.9M | $55.3M | $54.1M | $53.3M | $55.1M | ||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.8M | $3.1M | $2.7M | $4.1M | $5.8M | $7.2M | $5.5M | $7.0M | $9.1M | ||||||||||||||||
| Assets Current | $28.9M | $29.8M | $30.4M | $28.7M | $6.3M | ||||||||||||||||||||
| Repayments Of Related Party Debt | $5.5M | $275.2K | |||||||||||||||||||||||
| Issuance Of Preferred Stock Due To Antidilution | |||||||||||||||||||||||||
| Exercise Of Common Stock From Green Shoe Of Followon Offering Net Of Offering Costs | $2.5M | ||||||||||||||||||||||||
| Stock Issued During Period Value Exchange Of Related Party Payables And Warrants For Common Stock | $12.0M | ||||||||||||||||||||||||
| Issuance Of Common Stock Through Partial Exercise Of Underwriter Warrants | |||||||||||||||||||||||||
| Deferred Compensation Liability Current And Noncurrent | $306.3K | $306.3K | |||||||||||||||||||||||
| Deferred Offering Costs | $42.6K | ||||||||||||||||||||||||
| Deferred Compensation Liability Current | $306.3K | $306.3K | |||||||||||||||||||||||
| Accrued Liabilities Current | $42.6K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $7.3M | $2.4M | $1.7M | $660.6K | $678.0K | $194.9K |
| Increase Decrease In Employee Related Liabilities | $37.8K | -$4.0K | -$122.3K | $105.0K | $47.7K | -$19.3K |
| Share Based Compensation | $7.3M | $2.4M | $1.7M | $660.6K | $678.0K | $194.9K |
| Net Cash Provided By Used In Operating Activities | -$7.3M | -$6.5M | -$6.2M | -$4.3M | -$1.2M | -$293.3K |
| Net Cash Provided By Used In Financing Activities | $4.4M | -$7.5M | $2.8M | $29.8M | $215.0K | |
| Increase Decrease In Accounts Payable | $921.2K | $35.5K | -$526.7K | -$92.6K | $393.4K | |
| Increase Decrease In Interest Payable Net | $36.6K | $73.2K | $59.4K | |||
| Proceeds From Issuance Of Common Stock | $3.1M | $30.2M | ||||
| Proceeds From Issuance Initial Public Offering | $1.9M | |||||
| Payments For Repurchase Of Common Stock | $7.5M | |||||
| Proceeds From Issuance Of Private Placement | $2.5M | |||||
| Increase Decrease In Due To Related Parties | $2.5M | |||||
| Proceeds From Related Party Debt | $215.0K | |||||
| Proceeds From Repayments Of Related Party Debt | -$275.2K | |||||
| Increase Decrease In Deferred Compensation | $306.3K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $1.5M | $1.5M | $1.5M | $594.5K | $594.5K | $594.5K | $594.5K | $594.5K | $594.5K | $759.6K | $224.5K | $165.3K | $165.1K | $165.1K | $165.1K | $165.1K | $173.9K | $173.9K |
| Increase Decrease In Employee Related Liabilities | $8.4K | $4.9K | -$27.3K | -$144.0K | $4.5K | $51.5K | ||||||||||||
| Share Based Compensation | $1.5M | $594.5K | $594.5K | $165.3K | $165.1K | $173.9K | ||||||||||||
| Net Cash Provided By Used In Operating Activities | -$1.8M | -$1.8M | -$1.6M | -$1.9M | -$528.3K | |||||||||||||
| Net Cash Provided By Used In Financing Activities | $492.4K | $299.1K | -$5.5M | $2.3M | ||||||||||||||
| Increase Decrease In Accounts Payable | -$129.7K | $90.3K | -$120.0K | |||||||||||||||
| Increase Decrease In Interest Payable Net | $18.3K | $18.3K | ||||||||||||||||
| Proceeds From Issuance Of Common Stock | $299.1K | $2.5M | ||||||||||||||||
| Proceeds From Issuance Initial Public Offering | $492.4K | $299.1K | ||||||||||||||||
| Payments For Repurchase Of Common Stock | $5.5M | |||||||||||||||||
| Proceeds From Issuance Of Private Placement | ||||||||||||||||||
| Increase Decrease In Due To Related Parties | ||||||||||||||||||
| Proceeds From Related Party Debt | ||||||||||||||||||
| Proceeds From Repayments Of Related Party Debt | ||||||||||||||||||
| Increase Decrease In Deferred Compensation |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.21 | -$0.69 | -$0.61 | -$0.35 | -$0.20 | -$1.52 |
| Earnings Per Share Basic | $-1.21 | $-0.69 | $-0.61 | $-0.35 | ||
| Common Stock Shares Outstanding | 12.8M | 12.8M | 13.1M | 12.7M | 8.5M | |
| Common Stock Shares Issued | 12.8M | 12.8M | 13.1M | 12.7M | 8.5M | |
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Diluted Shares Outstanding | 13.0M | 12.8M | 12.9M | |||
| Weighted Average Number Of Shares Issued Basic | 12.8M | 12.9M | 12.9M | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 12.9M | 9.5M | 2.3M | |||
| Weighted Average Number Of Shares Outstanding Basic | 13.0M | 12.8M | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.30 | -$0.30 | -$0.25 | -$0.20 | -$0.20 | -$0.19 | -$0.19 | -$0.13 | -$0.17 | -$0.18 | -$0.06 | -$0.07 | -$0.06 | -$0.05 | -$0.03 | -$0.02 | -$0.03 | -$1.15 | ||
| Earnings Per Share Basic | $-0.30 | $-0.30 | $-0.25 | $-0.20 | $-0.20 | $-0.19 | $-0.19 | $-0.13 | $-0.17 | $-0.18 | $-0.06 | $-0.15 | $-0.07 | $-0.06 | $-0.05 | |||||
| Common Stock Shares Outstanding | 13.8M | 13.5M | 13.2M | 13.2M | 13.1M | 13.1M | 12.9M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 13.0M | 13.0M | 12.9M | 12.8M | 12.0M | |||
| Common Stock Shares Issued | 13.8M | 13.5M | 13.2M | 13.2M | 13.1M | 13.1M | 12.9M | 12.8M | 12.8M | 12.8M | 12.8M | 12.8M | 13.0M | 13.0M | 12.9M | 12.8M | 12.0M | |||
| Common Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Weighted Average Number Of Diluted Shares Outstanding | 13.6M | 13.4M | 13.2M | 13.1M | 12.9M | 12.9M | 12.8M | 12.8M | 12.8M | 12.8M | 12.9M | |||||||||
| Weighted Average Number Of Shares Issued Basic | 12.8M | 12.8M | 12.8M | 12.8M | 12.9M | 13.1M | 13.0M | 12.9M | 12.8M | |||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 13.0M | 12.9M | 12.8M | 8.8M | 8.6M | 8.5M | 291.8K | |||||||||||||
| Weighted Average Number Of Shares Outstanding Basic | 13.6M | 13.4M | 13.2M | 13.1M | 12.9M | 12.9M | 12.8M | 12.8M | 12.8M | |||||||||||
| Preferred Stock Shares Authorized | 10.0M | |||||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Investment Income Interest | $223.0K | $436.1K | $215.0K | $27.4K | $832.00 | |
| Adjustment For Amortization | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K |
| Stock Issued During Period Value New Issues | $1.9M | $6.2M | ||||
| Stock Repurchased During Period Value | $7.5M | |||||
| Additional Paid In Capital | $25.9M | |||||
| Due To Related Parties Current | $275.2K | $635.2K | ||||
| Conversion Of Stock Amount Converted1 | $2.0K | |||||
| Stock Issued During Period Value Other | $2.5M | |||||
| Stock Issued1 | $12.0M | |||||
| Stock Repurchased During Period Shares | ||||||
| Stock Issued During Period Value Stock Options Exercised | ||||||
| Stock Issued During Period Value New Issues Follow On Offering | $24.0M | |||||
| Stock Issued During Period Value Net Proceeds From Exercise Of Remaining Underwriter Warrants | ||||||
| Stock Issued During Period Value Issued For Services |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment Income Interest | $22.8K | $20.7K | $24.0K | $60.3K | $54.7K | $64.0K | $111.1K | $119.5K | $116.2K | $64.0K | $27.2K | $19.6K | $3.6K | $3.7K | $3.6K | |||
| Adjustment For Amortization | $903.00 | $903.00 | $903.00 | $903.00 | $903.00 | $902.00 | ||||||||||||
| Stock Issued During Period Value New Issues | $3.2M | $2.6M | $492.4K | $1.2M | $266.7K | $299.1K | $6.2M | |||||||||||
| Stock Repurchased During Period Value | $266.7K | $299.1K | $2.0M | $5.5M | ||||||||||||||
| Additional Paid In Capital | $59.7M | $59.6M | $59.4M | $56.7M | $32.6M | |||||||||||||
| Due To Related Parties Current | $635.2K | |||||||||||||||||
| Conversion Of Stock Amount Converted1 | ||||||||||||||||||
| Stock Issued During Period Value Other | $2.5M | |||||||||||||||||
| Stock Issued1 | ||||||||||||||||||
| Stock Repurchased During Period Shares | 0.00 | |||||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $2.5M | |||||||||||||||||
| Stock Issued During Period Value New Issues Follow On Offering | ||||||||||||||||||
| Stock Issued During Period Value Net Proceeds From Exercise Of Remaining Underwriter Warrants | $145.0K | |||||||||||||||||
| Stock Issued During Period Value Issued For Services | $2.5M |
Most recent annual filing with the SEC: April 15, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.